Topical delivery of anti-sense oligonucleotides using low-frequency sonophoresis

Pharmaceutical Research

Volumn 21, Issue 12, 2004, Pages 2219-2225

  Tezel, Ahmet ^a   Dokka, Sujatha ^b   Kelly, Susan ^b   Hardee, Gregory E ^b   Mitragotri, Samir ^a  

^a University of California   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

Inflammation; ODN; Oligonucleotides; Sonophoresis; Topical

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; FLUORESCEIN ISOTHIOCYANATE; SULFORHODAMINE B;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; IMMUNOHISTOCHEMISTRY; MACROMOLECULE; NONHUMAN; PRIORITY JOURNAL; SKIN PENETRATION; SKIN PERMEABILITY; SWINE; ULTRASOUND;

ADMINISTRATION, TOPICAL; ANIMALS; DRUG DELIVERY SYSTEMS; OLIGONUCLEOTIDES, ANTISENSE; PHONOPHORESIS; SKIN ABSORPTION; SWINE;

EID: 17644404442     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11095-004-7674-6     Document Type: Article

References (25)

1. G. Jarad, J. S. Simske, J. R. Sedor, and J. R. Schelling. Nucleic acid-based techniques for post-transcriptional regulation of molecular agents. Curr. Opin. Nephrol. Hpertens. 12:415-421 (2003).
2. C. Wraight and P. White. Antisense oligonucleotides in cutaneous therapy. Pharmacol. Ther. 90:89-104 (2001).
3. U. Mrowietz. The enigma of cyclosporin A treatment for psoriasis: systemic efficacy versus topical non-responsiveness. A review. Acta Derm. Venereol. 72:321-326 (1992).
4. F. P. Schmook, A. Stutz, and J. Reinhardt. Penetration of Sand-immune (cyclosporin A) in rat skin in vitro. Effects of penetration enhancers and solvents. Skin Pharmacol. 6:116-124 (1993).
5. J. Bouwstra, A. M. de Vries, A. G. Gooris, S. W. Bras, J. Brussee, and M. Ponec. Thermodynamic and Structural Aspects of the Skin Barrier. J. Control. Rel. 15:209-220 (1991).
6. R. M. Brand and P. L. Iversen. Iontophoretic delivery of atelomeric oligonucleotide. Pharm. Res. 13:851-854 (1996).
7. K. Li, A. H. Ghanem, C. L. Teng, G. E. Hardee, and W. I. Higuchi. Iontopohoretic transport of oligonucleotides across human epidermal membrane: a study of the Nernst-Planck model. J. Pharm. Sci. 90:915-931 (2001).
8. R. M. Brand, T. L. Hannah, J. Norris, and P. L. Iversen. Transdermal delivery of antisense oligonucleotides can induce changes in gene expression in vivo. Antisense Nucleic Acid Drug Dev. 11:1-6 (2001).
9. V. Regnier, N. De Morre, A. Jadoul, and V. Preat. Mechanisms of a phosphorothioate oligonucleotide delivery by skin electroporation. Int. J. Pharm. 184:147-156 (1999).
10. T. E. Zewert, U. F. Pliquett, R. Langer, and J. C. Weaver. Transdermal transport of DNA antisense oligonucleotides by electroporation. Biochem. Biophys. Res. Commun. 212:286-292 (1995).
11. R. C. Mehta, K. K. Strecker, S. R. Cooper, M. V. Templin, Y. J. Tsai, T. P. Condon, C. F. Bennett, and G. E. Hardee. Intercellular adhesion moleculae-1 supression in skin by topical delivery of anti-sense oligonucleotides. J. Invest. Dermatol. 115:805-812 (2000).
12. W. Lin, M. Cromier, A. Samiee, A. Griffin, B. Johnson, C.-L. Teng, G. E. Hardee, and P. E. Daddona. Transdermal delivery of antisense oligonucleotides with microprojection patch (Macroflux) technology. Pharm. Res. 18:1789-1793 (2001).
13. S. Mitragotri, D. Edwards, D. Blankschtein, and R. Langer. A mechanistic study of ultrasonically enhanced transdermal drug delivery. J. Pharm. Sci. 84:697-706 (1995).
14. S. Mitragotri and L. Le. Transdermal delivery of heparin and low-molecular weight heparin using low-frequency ultrasound. Pharm. Res. 18:1151-1156 (2000).
15. B. P. Monia, J. F. Johnston, D. J. Ecker, M. A. Zounes, W. F. Lima, and S. M. Freier. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J. Biol. Chem. 267:19954-19962 (1992).
16. B. P. Monia, E. A. Lesnik, C. Gonzalez, W. F. Lima, D. McGee, C. J. Guinosso, A. M. Kawasaki, P. D. Cook, and S. M. Freier. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268:14514-14522 (1993).
17. A. Tezel, A. Sens, J. Tuchscherer, and S. Mitragotri. Frequency dependence of sonophoresis. Pharm. Res. 18:1694-1700 (2001).
18. N. P. Katz, D. E. Shapiro, T. E. Hermann, J. Kost, and L. Custer. Rapid onset of cutaneous anesthesia with EMLA cream after pretreatment with a new ultrasound emitting device. Anesth. Analg. 98:371-376 (2004).
19. M. Butler, K. Stecker, and C. F. Bennet. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissue. Lab. Invest. 77:379-388 (1997).
20. S. Mitragotri, D. Blankschtein, and R. Langer. Ultrasound-mediated transdermal protein delivery. Science 269:850-853 (1995).
21. A. Tezel, A. Sens, and S. Mitragotri. Description of transdermal transport of hydrophilic solutes during low-frequency sonophoresis based on a modified porous pathway model. J. Pharm. Sci. 92:381-393 (2003).
22. W. Lin, M. Cormier, A. Samiee, A. Griffin, B. Johnson, C. L. Teng, G. E. Hardee, and P. E. Daddona. Transdermal delivery of antisense oligonucleotides with microprojection patch (Macroflux) technology. Pharm. Res. 18:1789-1793 (2001).
23. S. K. Li, A. H. Ghanem, C. L. Teng, G. E. Hardee, and W. I. Higuchi. Iontophoretic transport of oligonucleotides across human epidermal membrane: a study of the Nernst-Planck model. J. Pharm. Sci. 90:915-931 (2001).
24. V. Regnier, N. De Morre, A. Jadoul, and V. Preat. Mechanisms of a phosphorothioate oligonucleotide delivery by skin electroporation. Int. J. Pharm. 184:147-156 (1999).
25. A. Tezel, A. Sens, J. Tuchscherer, and S. Mitragotri. Frequency dependence of sonophoresis. Pharm. Res. 18:1694-1700 (2001).